Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis

Journal of Hepatology

Volumn 69, Issue 2, 2018, Pages 396-405

  Brandl, Katharina ^a   Hartmann, Phillipp ^b,c   Jih, Lily J ^b,d   Pizzo, Donald P ^b   Argemi, Josepmaria ^e   Ventura Cots, Meritxell ^e   Coulter, Sally ^f   Liddle, Christopher ^f   Ling, Lei ^g   Rossi, Stephen J ^g   DePaoli, Alex M ^g   Loomba, Rohit ^c   Mehal, Wajahat Z ^h,i   Fouts, Derrick E ^j   Lucey, Michael R ^k   Bosques Padilla, Francisco ^l   Mathurin, Philippe ^m   Louvet, Alexander ^m   Garcia Tsao, Guadalupe ^h,i   Verna, Elizabeth C ⁿ   Abraldes, Juan G ^o   Brown, Robert S ^p   Vargas, Victor ^q,r   Altamirano, Jose ^q   Caballería, Juan ^r,s   Shawcross, Debbie ^t   Stärkel, Peter ^u   Ho, Samuel B ^c,d   Bataller, Ramon ^e   Schnabl, Bernd ^c,d   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g NGM Bio   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^j J CRAIG VENTER INSTITUTE   (United States)

^k UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^l HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^m INSERM   (France)

ⁿ New York Presbyterian Columbia University Medical Center   (United States)

^o UNIVERSITY OF ALBERTA   (Canada)

^p WEILL CORNELL MEDICAL COLLEGE   (United States)

^q HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^r INSTITUTO DE SALUD CARLOS III   (Spain)

^s HOSPITAL CLÍNIC   (Spain)

^t KING S COLLEGE HOSPITAL   (United Kingdom)

^u CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

Bile acids; FGF19; Microbiome

Indexed keywords

BILE ACID; BILE ACID CONJUGATE; BILE SALT EXPORT PUMP; BILIRUBIN; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; DEOXYCHOLIC ACID; FIBROBLAST GROWTH FACTOR 19; GAMMA GLUTAMYLTRANSFERASE; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; HYODEOXYCHOLIC ACID; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; BIOLOGICAL MARKER; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BILIARY EPITHELIUM; BILIRUBIN BLOOD LEVEL; CELL INFILTRATION; CHEMICAL COMPOSITION; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CYP8B1 GENE; DISEASE SEVERITY; EPITHELIUM CELL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE; GENE EXPRESSION; HEPATOBILIARY SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; MALE; MASS SPECTROMETRY; MODEL FOR END STAGE LIVER DISEASE SCORE; MRNA EXPRESSION LEVEL; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BIOSYNTHESIS; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

BILE ACIDS AND SALTS; BIOMARKERS; CHOLESTASIS; CORRELATION OF DATA; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; NEUTROPHIL INFILTRATION; NEUTROPHILS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 85047085514     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.03.031     Document Type: Article

References (30)

1. Chacko, K.R., Reinus, J., Spectrum of alcoholic liver disease. Clin Liver Dis 20 (2016), 419–427.
2. Thursz, M.R., Forrest, E.H., Ryder, S., STOPAH investigators. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 373 (2015), 282–283.
3. Maddrey, W.C., Boitnott, J.K., Bedine, M.S., Weber, F.L. Jr., Mezey, E., White, R.I. Jr., Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75 (1978), 193–199.
4. Dominguez, M., Rincon, D., Abraldes, J.G., Miquel, R., Colmenero, J., Bellot, P., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 103 (2008), 2747–2756.
5. Mathurin, P., Lucey, M.R., Management of alcoholic hepatitis. J Hepatol 56 (2012), S39–S45.
6. Altamirano, J., Miquel, R., Katoonizadeh, A., Abraldes, J.G., Duarte-Rojo, A., Louvet, A., et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 146 (2014), 1231–1239 e1231–e1236.
7. Halilbasic, E., Baghdasaryan, A., Trauner, M., Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis 17 (2013), 161–189.
8. Trinchet, J.C., Gerhardt, M.F., Balkau, B., Munz, C., Poupon, R.E., Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J Hepatol 21 (1994), 235–240.
9. Schaap, F.G., van der Gaag, N.A., Gouma, D.J., Jansen, P.L., High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49 (2009), 1228–1235.
10. Wunsch, E., Milkiewicz, M., Wasik, U., Trottier, J., Kempinska-Podhorodecka, A., Elias, E., et al. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Sci Rep, 5, 2015, 13462.
11. Li, Z., Lin, B., Lin, G., Wu, Y., Jie, Y., Li, X., et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One, 12, 2017, e0178580.
12. Bajaj, J.S., Kakiyama, G., Zhao, D., Takei, H., Fagan, A., Hylemon, P., et al. Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis. Alcohol Clin Exp Res 41 (2017), 1857–1865.
13. Fang, S., Suh, J.M., Reilly, S.M., Yu, E., Osborn, O., Lackey, D., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21 (2015), 159–165.
14. R: A language and environment for statistical computing [computer program]. http://www.R-project.org/2014.
15. Mouzaki, M., Wang, A.Y., Bandsma, R., Comelli, E.M., Arendt, B.M., Zhang, L., et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One, 11, 2016, e0151829.
16. Li, Y., Zhang, W., Doughtie, A., Cui, G., Li, X., Pandit, H., et al. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Oncotarget 7 (2016), 52329–52339.
17. Li, T., Apte, U., Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. Adv Pharmacol 74 (2015), 263–302.
18. Song, K.H., Li, T., Owsley, E., Strom, S., Chiang, J.Y., Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49 (2009), 297–305.
19. Lee, J.M., Trauner, M., Soroka, C.J., Stieger, B., Meier, P.J., Boyer, J.L., Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 118 (2000), 163–172.
20. Denk, G.U., Soroka, C.J., Takeyama, Y., Chen, W.S., Schuetz, J.D., Boyer, J.L., Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40 (2004), 585–591.
21. Bohan, A., Chen, W.S., Denson, L.A., Held, M.A., Boyer, J.L., Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 278 (2003), 36688–36698.
22. Kakiyama, G., Hylemon, P.B., Zhou, H., Pandak, W.M., Heuman, D.M., Kang, D.J., et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol 306 (2014), G929–G937.
23. Naugler, W.E., Tarlow, B.D., Fedorov, L.M., Taylor, M., Pelz, C., Li, B., et al. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology 149 (2015), 728–740 e715.
24. Mutanen, A., Lohi, J., Heikkila, P., Jalanko, H., Pakarinen, M.P., Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. J Hepatol 62 (2015), 1391–1397.
25. Zhou, M., Learned, R.M., Rossi, S.J., DePaoli, A.M., Tian, H., Ling, L., Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63 (2016), 914–929.
26. Hartmann, P., Hochrath, K., Horvath, A., Chen, P., Seebauer, C.T., Llorente, C., et al. Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice. Hepatology, 2017 Nov 21 [Epub ahead of print].
27. Alvarez-Sola, G., Uriarte, I., Latasa, M.U., Jimenez, M., Barcena-Varela, M., Santamaria, E., et al. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death Dis, 8, 2017, e3083.
28. Nevens, F., Andreone, P., Mazzella, G., Strasser, S.I., Bowlus, C., Invernizzi, P., et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375 (2016), 631–643.
29. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
30. Harrison, S.A., Rinella, M.E., Abdelmalek, M.F., Trotter, J.F., Paredes, A.H., Arnold, H.L., et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391 (2018), 1174–1185.